Who
Patrick O'Brien
COO
Company insider
Files Form 4 as: COO, Arrowhead Pharmaceuticals.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $23.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Dec 2014
- Last trade
- 6 Jan 2026
- Last filed
- 8 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —440 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —440 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —540 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —440 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —440 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K2,700 at $64.44 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $59K900 at $66.01 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $21K313 at $68.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $37K600 at $61.12 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $56K900 at $62.25 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $369K5,873 at $62.91 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $150K2,336 at $64.04 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,12846 at $68.00 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Patrick O'Brien; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.